Serum Levels of Copeptin are Decreased in Gestational Diabetes Mellitus

Abstract

Objective: Copeptin, the c-terminal part of pro-Arginine vasopressin, has recently been introduced as a novel risk factor to develop facets of the metabolic syndrome. However, regulation of copeptin in pregnancy-associated metabolic disease, i. e., gestational diabetes mellitus (GDM), has not been fully understood, so far.

Patients and Measurements: For this study, 74 GDM patients and 74 healthy, pregnant, age-, body mass index-, and gestational age-matched controls were recruited. Serum levels of copeptin were quantified by an illuminometric assay. Furthermore, copeptin concentrations were correlated to biochemical and anthropometric markers of obesity, glucose and lipid metabolism, renal function, and inflammation.

Results: Median [interquartile range] serum copeptin levels were significantly lower in subjects with GDM (3.5 [2.0] pmol/l) as compared to controls (4.4 [3.2] pmol/l) (p<0.05). Furthermore, GDM remained an independent predictor of circulating copeptin in multivariate regression analysis (p<0.05). Moreover, copeptin was independently associated with gestational age at blood sampling (p<0.05).

Conclusions: Copeptin serum levels are significantly lower in GDM as compared to healthy pregnant controls. Further studies are needed to better clarify the pathophysiological role of copeptin in GDM.

Key words

arginine vasopressin - copeptin - gestational diabetes mellitus - insulin resistance - pregnancy

^* These authors equally contributed to this work

• References

• 1 Fadl HE, Östlund IKM, Magnuson AFK et al. Maternal and neonatal outcomes and time trends of gestational diabetes mellitus in Sweden from 1991 to 2003. Diabetic Medicine 2010; 27: 436-441
• 2 Kim C, Newton KM, Knopp RH. Gestational Diabetes and the Incidence of Type 2 Diabetes. Diabetes Care 2002; 25: 1862-1868
• 3 Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care 2008; 31: 1668-1669
• 4 Hillier TA, Pedula KL, Schmidt MM et al. Childhood obesity and metabolic imprinting. Diabetes Care 2007; 30: 2287-2292
• 5 Silverman BL, Metzger BE, Cho NH et al. Impaired glucose tolerance in adolescent offspring of diabetic mothers: Relationship to fetal hyperinsulinism. Diabetes Care 1995; 18: 611-617
• 6 Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26: 2500-2504
• 7 Enhörning S, Wang TJ, Nilsson PM et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010; 121: 2102-2108
• 8 Enhörning S, Bankir L, Bouby N et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö diet and cancer study cardiovascular cohort. Int J Obes 2013; 37: 598-603
• 9 Enhörning S, Struck J, Wirfält E et al. A unifying factor behind the metabolic syndrome. JCEM 2011; 96: E1065-E1072
• 10 Maier C, Clodi M, Neuhold S et al. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 2009; 32: 1890-1895
• 11 Fenske W, Wanner C, Allolio B et al. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. JASN 2011; 22: 782-790
• 12 American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 36: S67-S74
• 13 Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 14 Saleem U, Khaleghi M, Morgenthaler NG et al. Plasma carboxy-terminal provasopressin (Copeptin): A novel marker of insulin resistance and metabolic syndrome. JCEM 2009; 94: 2558-2564
• 15 Morgenthaler NG. Copeptin: A biomarker of cardiovascular and renal function. Congestive Heart Failure 2010; 16: S37-S44
• 16 Bergen SS, Sullivan R, Hilton JG et al. Glycogenolytic effect of vasopressin in the canine liver. American Journal of Physiology – Legacy Content 1960; 199: 136-138
• 17 Hensen J, Hader O, Bahr V et al. Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man. JCEM 1988; 66: 668-671
• 18 Gallo-Payet N, Guillon G. Regulation of adrenocortical function by vasopressin. Hormone and Metabolic Research 2007; 30: 360-367
• 19 Mazzocchi G, Malendowicz LK, Rebuffat P et al. Arginine-vasopressin stimulates CRH and ACTH release by rat adrenal medulla, acting via the V1 receptor subtype and a protein kinase C-dependent pathway. Peptides 1997; 18: 191-195
• 20 Koshimizu T, Nakamura K, Egashira N et al. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 2012; 92: 1813-1864
• 21 Fujiwara Y, Hiroyama M, Sanbe A et al. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol 2007; 584: 235-244
• 22 DeVane GW. Vasopressin levels during pregnancy and labor. J Reprod Med 1985; 30: 324-327
• 23 Oncul M, Tuten A, Kucur M et al. Copeptin concentrations are not elevated in gestational diabetes mellitus. Arch Gynecol Obstet 2013; 288: 1045-1049
• 24 Aydin S, Kuloglu T, Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides 2013; 47: 66-70